ZA200200896B - Pteridinones as kinase inhibitors. - Google Patents
Pteridinones as kinase inhibitors. Download PDFInfo
- Publication number
- ZA200200896B ZA200200896B ZA200200896A ZA200200896A ZA200200896B ZA 200200896 B ZA200200896 B ZA 200200896B ZA 200200896 A ZA200200896 A ZA 200200896A ZA 200200896 A ZA200200896 A ZA 200200896A ZA 200200896 B ZA200200896 B ZA 200200896B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- amino
- mono
- dialkylamino
- pteridin
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 2
- VWXIHLCLIOQWRA-UHFFFAOYSA-N 1h-pteridin-2-one Chemical class N1=CC=NC2=NC(O)=NC=C21 VWXIHLCLIOQWRA-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 90
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 66
- 125000003545 alkoxy group Chemical group 0.000 claims description 64
- 150000002367 halogens Chemical class 0.000 claims description 62
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 60
- 229910052736 halogen Inorganic materials 0.000 claims description 59
- -1 COyZ Chemical compound 0.000 claims description 48
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 125000003118 aryl group Chemical group 0.000 claims description 42
- RGJOEKWQDUBAIZ-HDCXRZRFSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3s)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-HDCXRZRFSA-N 0.000 claims description 41
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 41
- 125000002837 carbocyclic group Chemical group 0.000 claims description 39
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 26
- 150000003573 thiols Chemical class 0.000 claims description 26
- 150000003857 carboxamides Chemical class 0.000 claims description 25
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 150000002825 nitriles Chemical class 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 125000004001 thioalkyl group Chemical group 0.000 claims description 23
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- LJDZFAPLPVPTBD-UHFFFAOYSA-N nitroformic acid Chemical compound OC(=O)[N+]([O-])=O LJDZFAPLPVPTBD-UHFFFAOYSA-N 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 22
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 18
- 239000001301 oxygen Substances 0.000 claims description 18
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims description 17
- 125000002431 aminoalkoxy group Chemical group 0.000 claims description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 16
- 125000004193 piperazinyl group Chemical group 0.000 claims description 16
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 15
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 15
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 13
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 150000001408 amides Chemical class 0.000 claims description 12
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000002757 morpholinyl group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003102 growth factor Substances 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 208000037803 restenosis Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 102000020233 phosphotransferase Human genes 0.000 claims description 7
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 230000033115 angiogenesis Effects 0.000 claims description 5
- 101150073031 cdk2 gene Proteins 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000006540 piperadinylalkyl group Chemical group 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 241000450599 DNA viruses Species 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 4
- 241001493065 dsRNA viruses Species 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 101150012716 CDK1 gene Proteins 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 claims description 3
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 claims description 3
- 206010057469 Vascular stenosis Diseases 0.000 claims description 3
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- TWLWOOPCEXYVBE-UHFFFAOYSA-N 5-fluoro-2-(6-fluoro-2-methylbenzimidazol-1-yl)-4-n-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine Chemical compound CC1=NC2=CC=C(F)C=C2N1C(N=1)=NC(N)=C(F)C=1NC1=CC=C(C(F)(F)F)C=C1 TWLWOOPCEXYVBE-UHFFFAOYSA-N 0.000 claims 34
- 239000000126 substance Substances 0.000 claims 25
- 238000004519 manufacturing process Methods 0.000 claims 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- YQYPLGPPOZBEJU-UHFFFAOYSA-N acetyloxycarbamic acid Chemical class CC(=O)ONC(O)=O YQYPLGPPOZBEJU-UHFFFAOYSA-N 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- UPOQNAOTDRSRGG-UHFFFAOYSA-N 1-[2-[4-[4-[3-(3-aminopyrrolidin-1-yl)propyl]piperidin-1-yl]anilino]pteridin-7-yl]-3-tert-butylurea Chemical compound N=1C2=NC(NC(=O)NC(C)(C)C)=CN=C2C=NC=1NC(C=C1)=CC=C1N(CC1)CCC1CCCN1CCC(N)C1 UPOQNAOTDRSRGG-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- IYNMEUFWCCKCDP-UHFFFAOYSA-N 2-(3-chloro-4-fluoroanilino)-8-cyclopentylpteridin-7-one Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=C(N=CC(=O)N2C3CCCC3)C2=N1 IYNMEUFWCCKCDP-UHFFFAOYSA-N 0.000 claims 1
- MOSSYTVPDMVLCJ-UHFFFAOYSA-N 2-(3-chloro-4-piperazin-1-ylanilino)-8-cyclopentylpteridin-7-one Chemical compound C=1C=C(N2CCNCC2)C(Cl)=CC=1NC(N=C12)=NC=C1N=CC(=O)N2C1CCCC1 MOSSYTVPDMVLCJ-UHFFFAOYSA-N 0.000 claims 1
- NTFVGDRIVOBXGC-UHFFFAOYSA-N 2-[3-chloro-4-(3-chloropyrrolidin-1-yl)anilino]-8-cyclopentylpteridin-7-one Chemical compound C1C(Cl)CCN1C(C(=C1)Cl)=CC=C1NC1=NC=C(N=CC(=O)N2C3CCCC3)C2=N1 NTFVGDRIVOBXGC-UHFFFAOYSA-N 0.000 claims 1
- JFRQYWUUGCZUSX-UHFFFAOYSA-N 2-[3-chloro-4-[3-chloro-4-(trifluoromethyl)pyrrolidin-1-yl]anilino]-8-cyclopentylpteridin-7-one Chemical compound C1C(Cl)C(C(F)(F)F)CN1C(C(=C1)Cl)=CC=C1NC1=NC=C(N=CC(=O)N2C3CCCC3)C2=N1 JFRQYWUUGCZUSX-UHFFFAOYSA-N 0.000 claims 1
- YZDQWJHDAXVFPA-UHFFFAOYSA-N 2-[4-[3-(2-aminopropan-2-yl)pyrrolidin-1-yl]-3-chloroanilino]-8-cyclopentylpteridin-7-one Chemical compound C1C(C(C)(N)C)CCN1C(C(=C1)Cl)=CC=C1NC1=NC=C(N=CC(=O)N2C3CCCC3)C2=N1 YZDQWJHDAXVFPA-UHFFFAOYSA-N 0.000 claims 1
- MILWOTKFDYWITQ-UHFFFAOYSA-N 2-methyl-6,8-dihydro-5h-pteridin-7-one Chemical compound N1CC(=O)NC2=NC(C)=NC=C21 MILWOTKFDYWITQ-UHFFFAOYSA-N 0.000 claims 1
- BRFNADVHVKIRKP-UHFFFAOYSA-N 4-[[6-(3,5-dichloro-2,6-dimethoxypyridin-4-yl)-8-methyl-7-oxopteridin-2-yl]amino]-n,n-diethylbenzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1NC1=NC=C(N=C(C=2C(=C(OC)N=C(OC)C=2Cl)Cl)C(=O)N2C)C2=N1 BRFNADVHVKIRKP-UHFFFAOYSA-N 0.000 claims 1
- XTFXYOOJMPYHGN-UHFFFAOYSA-N 4-[[6-(3,5-dichloropyridin-4-yl)-8-methyl-7-oxopteridin-2-yl]amino]-n,n-diethylbenzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1NC1=NC=C(N=C(C=2C(=CN=CC=2Cl)Cl)C(=O)N2C)C2=N1 XTFXYOOJMPYHGN-UHFFFAOYSA-N 0.000 claims 1
- PMVFPBHHPYGTOT-UHFFFAOYSA-N 6-(2,6-dichloro-3-hydroxyphenyl)-8-methyl-2-(4-morpholin-4-ylanilino)pteridin-7-one Chemical compound N=1C=C2N=C(C=3C(=C(O)C=CC=3Cl)Cl)C(=O)N(C)C2=NC=1NC(C=C1)=CC=C1N1CCOCC1 PMVFPBHHPYGTOT-UHFFFAOYSA-N 0.000 claims 1
- AAGCLPSNCFMSER-UHFFFAOYSA-N 6-(2,6-dichloro-3-methoxyphenyl)-8-methyl-2-(4-morpholin-4-ylanilino)pteridin-7-one Chemical compound COC1=CC=C(Cl)C(C=2C(N(C)C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3N=2)=O)=C1Cl AAGCLPSNCFMSER-UHFFFAOYSA-N 0.000 claims 1
- XDYSEPCCXCCKCB-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpteridin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(N=C(C=2C(=CC=CC=2Cl)Cl)C(=O)N2C)C2=N1 XDYSEPCCXCCKCB-UHFFFAOYSA-N 0.000 claims 1
- XKZVCLVXJAUEEE-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylanilino)pteridin-7-one Chemical compound N=1C=C2N=C(C=3C(=CC=CC=3Cl)Cl)C(=O)N(C)C2=NC=1NC(C=C1)=CC=C1N1CCOCC1 XKZVCLVXJAUEEE-UHFFFAOYSA-N 0.000 claims 1
- SFMVMYSZIILQHZ-UHFFFAOYSA-N 6-(3,5-dibromopyridin-4-yl)-8-methyl-2-(4-morpholin-4-ylanilino)pteridin-7-one Chemical compound N=1C=C2N=C(C=3C(=CN=CC=3Br)Br)C(=O)N(C)C2=NC=1NC(C=C1)=CC=C1N1CCOCC1 SFMVMYSZIILQHZ-UHFFFAOYSA-N 0.000 claims 1
- VTZRVCJFRVSILI-UHFFFAOYSA-N 6-(3,5-dichloro-2,6-dimethoxypyridin-4-yl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpteridin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(N=C(C=2C(=C(OC)N=C(OC)C=2Cl)Cl)C(=O)N2C)C2=N1 VTZRVCJFRVSILI-UHFFFAOYSA-N 0.000 claims 1
- JTWZNNWPAFJACJ-UHFFFAOYSA-N 6-(3,5-dichloro-2,6-dimethoxypyridin-4-yl)-8-methyl-2-(4-morpholin-4-ylanilino)pteridin-7-one Chemical compound COC1=NC(OC)=C(Cl)C(C=2C(N(C)C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3N=2)=O)=C1Cl JTWZNNWPAFJACJ-UHFFFAOYSA-N 0.000 claims 1
- ASIIYBZDAMLQSS-UHFFFAOYSA-N 6-(3,5-dimethoxyphenyl)-8-ethyl-2-(pyridin-4-ylamino)pteridin-7-one Chemical compound N=1C=C2N=C(C=3C=C(OC)C=C(OC)C=3)C(=O)N(CC)C2=NC=1NC1=CC=NC=C1 ASIIYBZDAMLQSS-UHFFFAOYSA-N 0.000 claims 1
- ZSUTVDRHBZDMKT-UHFFFAOYSA-N 8-cyclopentyl-2-(4-fluoro-3-methylanilino)-6-methylpteridin-7-one Chemical compound C1=C(F)C(C)=CC(NC=2N=C3N(C4CCCC4)C(=O)C(C)=NC3=CN=2)=C1 ZSUTVDRHBZDMKT-UHFFFAOYSA-N 0.000 claims 1
- WPKSQIGQEAHERC-UHFFFAOYSA-N 8-cyclopentyl-2-(4-fluoro-3-methylanilino)pteridin-7-one Chemical compound C1=C(F)C(C)=CC(NC=2N=C3N(C4CCCC4)C(=O)C=NC3=CN=2)=C1 WPKSQIGQEAHERC-UHFFFAOYSA-N 0.000 claims 1
- FHADSBHFOMZHRE-UHFFFAOYSA-N 8-cyclopentyl-2-(4-morpholin-4-ylanilino)pteridin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C=NC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 FHADSBHFOMZHRE-UHFFFAOYSA-N 0.000 claims 1
- OTCSXNHFLPNXHW-UHFFFAOYSA-N 8-cyclopentyl-2-(pyridin-4-ylamino)pteridin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C=NC2=CN=C1NC1=CC=NC=C1 OTCSXNHFLPNXHW-UHFFFAOYSA-N 0.000 claims 1
- IKXHGNCGYSIJLT-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)anilino]pteridin-7-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(N=CC(=O)N2C3CCCC3)C2=N1 IKXHGNCGYSIJLT-UHFFFAOYSA-N 0.000 claims 1
- MDECEBVDPQGMBN-UHFFFAOYSA-N 8-cyclopentyl-2-[4-[4-(2-hydroxyethyl)-3,5-dimethylpiperazin-1-yl]anilino]-5-methyl-6h-pteridin-7-one Chemical compound C1C(C)N(CCO)C(C)CN1C(C=C1)=CC=C1NC1=NC=C(N(C)CC(=O)N2C3CCCC3)C2=N1 MDECEBVDPQGMBN-UHFFFAOYSA-N 0.000 claims 1
- GLDCPCUCHSKBFQ-UHFFFAOYSA-N 8-cyclopentyl-2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]-5-methyl-6h-pteridin-7-one Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCN(CCO)CC3)=NC=C2N(C)CC(=O)N1C1CCCC1 GLDCPCUCHSKBFQ-UHFFFAOYSA-N 0.000 claims 1
- GNVUEPCWSQCZLT-UHFFFAOYSA-N 8-cyclopentyl-2-[4-[4-(3-morpholin-4-ylpropyl)piperidin-1-yl]anilino]pteridin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C=NC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCC1CCCN1CCOCC1 GNVUEPCWSQCZLT-UHFFFAOYSA-N 0.000 claims 1
- BOTIHYDKMILPFU-UHFFFAOYSA-N 8-cyclopentyl-2-[4-[4-[3-(2h-tetrazol-5-yl)propyl]piperidin-1-yl]anilino]pteridin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C=NC2=CN=C1NC(C=C1)=CC=C1N(CC1)CCC1CCCC1=NN=NN1 BOTIHYDKMILPFU-UHFFFAOYSA-N 0.000 claims 1
- FMCDMQJLMPRJLV-UHFFFAOYSA-N 8-cyclopentyl-5-methyl-2-(4-morpholin-4-ylanilino)-6h-pteridin-7-one Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCOCC3)=NC=C2N(C)CC(=O)N1C1CCCC1 FMCDMQJLMPRJLV-UHFFFAOYSA-N 0.000 claims 1
- RGRBSDXLEVJXBQ-UHFFFAOYSA-N 8-cyclopentyl-5-methyl-2-(4-piperazin-1-ylanilino)-6h-pteridin-7-one Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2N(C)CC(=O)N1C1CCCC1 RGRBSDXLEVJXBQ-UHFFFAOYSA-N 0.000 claims 1
- JVTTYXFLKZSRJH-UHFFFAOYSA-N 8-cyclopentyl-6-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]pteridin-7-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(N=C(C)C(=O)N2C3CCCC3)C2=N1 JVTTYXFLKZSRJH-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- GRKUXCWELVWVMZ-UHFFFAOYSA-N amino acetate Chemical class CC(=O)ON GRKUXCWELVWVMZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 claims 1
- GEYIKMNUUVRSPH-UHFFFAOYSA-N n,n-diethyl-4-[(8-methyl-7-oxo-6-phenylpteridin-2-yl)amino]benzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1NC1=NC=C(N=C(C=2C=CC=CC=2)C(=O)N2C)C2=N1 GEYIKMNUUVRSPH-UHFFFAOYSA-N 0.000 claims 1
- MVSVAVCVURFYQW-UHFFFAOYSA-N n-[4-[(8-cyclopentyl-7-oxopteridin-2-yl)amino]phenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1NC1=NC=C(N=CC(=O)N2C3CCCC3)C2=N1 MVSVAVCVURFYQW-UHFFFAOYSA-N 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- JUIGPVOQGFLBAL-UHFFFAOYSA-N pteridine-6,7-dione Chemical compound C1=NC=NC2=NC(=O)C(=O)N=C21 JUIGPVOQGFLBAL-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 108091007914 CDKs Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 101150053721 Cdk5 gene Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- 150000003195 pteridines Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- ICRVYCIIYYZHJS-UHFFFAOYSA-N 3,4,6,8-tetrahydro-2h-pteridin-7-one Chemical class C1NCN=C2NC(=O)CN=C21 ICRVYCIIYYZHJS-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HNSVDKLARSSFGE-UHFFFAOYSA-N 5,8-dihydropteridine-6,7-dione Chemical class N1=CN=C2NC(=O)C(=O)NC2=C1 HNSVDKLARSSFGE-UHFFFAOYSA-N 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150093908 PDGFRB gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15409599P | 1999-09-15 | 1999-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200200896B true ZA200200896B (en) | 2003-07-30 |
Family
ID=22549985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200200896A ZA200200896B (en) | 1999-09-15 | 2002-01-31 | Pteridinones as kinase inhibitors. |
Country Status (29)
Country | Link |
---|---|
US (2) | US7169778B2 (es) |
EP (1) | EP1409487A1 (es) |
JP (1) | JP2003509425A (es) |
KR (1) | KR20020027649A (es) |
CN (1) | CN1373763A (es) |
AP (1) | AP2002002479A0 (es) |
AU (1) | AU777468B2 (es) |
BG (1) | BG106594A (es) |
BR (1) | BR0013952A (es) |
CA (1) | CA2393896A1 (es) |
CR (1) | CR6586A (es) |
CZ (1) | CZ2002846A3 (es) |
DZ (1) | DZ3186A1 (es) |
EA (1) | EA005287B1 (es) |
EE (1) | EE200200140A (es) |
HK (1) | HK1048992A1 (es) |
HU (1) | HUP0202713A3 (es) |
IL (1) | IL148614A0 (es) |
IS (1) | IS6298A (es) |
MA (1) | MA26819A1 (es) |
MX (1) | MXPA02001108A (es) |
NO (1) | NO20021239L (es) |
NZ (1) | NZ516872A (es) |
OA (1) | OA12010A (es) |
PL (1) | PL353269A1 (es) |
SK (1) | SK3542002A3 (es) |
WO (1) | WO2001019825A1 (es) |
YU (1) | YU18502A (es) |
ZA (1) | ZA200200896B (es) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276506B2 (en) | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
US6858608B2 (en) * | 2001-01-09 | 2005-02-22 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
WO2002076985A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
US6887873B2 (en) | 2001-03-23 | 2005-05-03 | Aventis Pharma S.A. | Triazine derivatives and their application as antitelomerase agents |
SE0101322D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
US20030176443A1 (en) * | 2001-05-16 | 2003-09-18 | Matthias Stein-Gerlach | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
EA007062B1 (ru) * | 2001-09-04 | 2006-06-30 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств |
WO2003032994A2 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
ES2314106T3 (es) * | 2001-10-17 | 2009-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion. |
PL220952B1 (pl) | 2002-01-22 | 2016-01-29 | Warner Lambert Co | 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony |
DE10212100A1 (de) * | 2002-03-11 | 2003-10-23 | Schering Ag | CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
AU2003250701A1 (en) * | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
US7067658B2 (en) | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
EP2039683B1 (en) * | 2002-10-03 | 2012-12-19 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US7629347B2 (en) * | 2002-10-09 | 2009-12-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
PL377795A1 (pl) * | 2002-11-28 | 2006-02-20 | Schering Aktiengesellschaft | Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych |
EP1590341B1 (en) * | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
PT1599478E (pt) * | 2003-02-26 | 2007-05-31 | Boehringer Ingelheim Pharma | Di-hidropteridinonas, proceso para a sua preparação e a sua utilização como medicamento |
CN1849318B (zh) | 2003-07-30 | 2011-10-12 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法 |
GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
CA2570494A1 (en) * | 2004-06-23 | 2006-01-05 | Irm Llc | Pteridine derivatives as protein kinase inhibitors |
DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
US7423051B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 2,6-diaminopyridine derivatives |
US7423053B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 4-Aminothiazole derivatives |
DE102004034623A1 (de) * | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
JP2008510770A (ja) * | 2004-08-26 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Plk阻害剤としての新規プテリジノン |
CA2578560A1 (en) | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for the production thereof, and use thereof as a medicament |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
US7767687B2 (en) * | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
WO2007095188A2 (en) | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
CN101448830A (zh) * | 2006-05-19 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 作为抗增殖剂的二氢碟啶化合物 |
WO2008009909A1 (en) * | 2006-07-17 | 2008-01-24 | Astrazeneca Ab | Pteridimones as modulators of polo-like kinase |
WO2008009079A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
WO2008040951A1 (en) * | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Compounds |
US7893066B2 (en) | 2006-10-05 | 2011-02-22 | Gilead Palo Alto, Inc. | Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors |
BRPI0717502A2 (pt) | 2006-10-05 | 2015-06-16 | Cv Therapeutics Inc | Compostos heterocíclicos contendo nitrogênio bacíclico para uso como inibidores de estearoil-coa desaturase. |
CA2673683C (en) | 2007-01-11 | 2014-07-29 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
EP1953163A1 (en) | 2007-02-01 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pteridinone derivatives as PI3-kinases inhibitors |
CA2681560A1 (en) | 2007-04-09 | 2008-10-16 | Cv Therapeutics, Inc. | Pteridinone derivatives for use as stearoyl coa desaturase inhibitors |
US8329695B2 (en) | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
WO2009042711A1 (en) | 2007-09-25 | 2009-04-02 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
EP2215091B1 (en) | 2007-12-04 | 2016-03-30 | Nerviano Medical Sciences S.r.l. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
CA2710039C (en) * | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
CA2719288A1 (en) | 2008-04-04 | 2009-11-12 | Gilead Sciences, Inc. | Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors |
WO2010006438A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
PL2364314T3 (pl) | 2008-12-09 | 2014-08-29 | Gilead Sciences Inc | Modulatory receptorów Toll-podobnych |
PL2477987T3 (pl) | 2009-09-14 | 2018-06-29 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych |
CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
MX2012003484A (es) | 2009-09-25 | 2012-04-20 | Vertex Pharma | Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa. |
RU2012116526A (ru) | 2009-09-25 | 2013-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы |
WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
WO2011101369A1 (en) | 2010-02-17 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
US8987272B2 (en) | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
EP2776444A4 (en) | 2011-11-10 | 2015-07-22 | Osi Pharmaceuticals Llc | dihydropteridinones |
CN106008511B (zh) * | 2012-05-14 | 2018-08-14 | 华东理工大学 | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
BR112015022191A8 (pt) | 2013-03-15 | 2018-01-23 | Celgene Avilomics Res Inc | compostos heteroarila e usos dos mesmos |
MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
DK3122359T3 (da) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer |
US10085982B2 (en) | 2014-03-26 | 2018-10-02 | Astex Therapeutics Ltd | Combinations |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
WO2015193228A1 (de) * | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe |
KR102019572B1 (ko) | 2014-07-11 | 2019-09-06 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 톨-유사 수용체의 조정제 |
CN110305133A (zh) | 2014-09-16 | 2019-10-08 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
KR101978809B1 (ko) | 2014-09-16 | 2019-05-15 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체 조정제를 제조하는 방법 |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
DK3097102T3 (en) | 2015-03-04 | 2018-01-22 | Gilead Sciences Inc | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
CN106279173A (zh) * | 2015-05-29 | 2017-01-04 | 华东理工大学 | 蝶啶酮衍生物作为egfr抑制剂的应用 |
AU2016328693B2 (en) | 2015-09-23 | 2021-03-11 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
SI3353177T1 (sl) | 2015-09-23 | 2020-08-31 | Janssen Pharmaceutica Nv | Triciklični heterocikli za zdravljenje raka |
CN106892922B (zh) * | 2015-12-18 | 2019-04-19 | 华东理工大学 | 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用 |
CN107151249B (zh) * | 2016-03-04 | 2020-08-14 | 华东理工大学 | 作为flt3抑制剂的蝶啶酮衍生物及应用 |
MA46093A (fr) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
CN108721298A (zh) * | 2017-04-19 | 2018-11-02 | 华东理工大学 | 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用 |
EP3833353A4 (en) * | 2018-08-10 | 2022-08-24 | Yale University | SMALL MOLECULAR PI5P4K ALPHA/BETA INHIBITORS AND METHODS OF TREATMENT THEREOF |
CN111217815B (zh) * | 2018-11-27 | 2021-06-18 | 沈阳药科大学 | 含有喋啶酮骨架的化合物及其制备方法和应用 |
TWI748317B (zh) * | 2019-01-03 | 2021-12-01 | 美商建南德克公司 | 吡啶并-嘧啶酮與喋啶酮化合物及使用方法 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
CN110357885A (zh) * | 2019-07-24 | 2019-10-22 | 江南大学 | 一种蝶啶类化合物及其在药学上的应用 |
CN113801118A (zh) * | 2020-06-12 | 2021-12-17 | 华东理工大学 | 作为rsk抑制剂的蝶啶酮衍生物及其应用 |
WO2022177302A1 (ko) * | 2021-02-17 | 2022-08-25 | 보령제약 주식회사 | Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도 |
CN113087708A (zh) * | 2021-04-06 | 2021-07-09 | 南方医科大学 | 一种蝶啶酮类化合物及其应用 |
WO2023046114A1 (zh) * | 2021-09-24 | 2023-03-30 | 华东理工大学 | 蝶啶酮衍生物及其应用 |
CN115010711A (zh) * | 2022-07-12 | 2022-09-06 | 江南大学 | 一种蝶啶7(8h)-酮类化合物及其在药学上的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53124296A (en) * | 1977-04-05 | 1978-10-30 | Mitsubishi Chem Ind Ltd | Penicillin derivatives |
ES2203642T3 (es) * | 1995-06-07 | 2004-04-16 | Pfizer Inc. | Derivados de pirimidina heterociclicos con anillos condensados. |
US6395733B1 (en) * | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
JPH1180131A (ja) * | 1997-09-01 | 1999-03-26 | Mitsubishi Chem Corp | エチニルピリミジン誘導体 |
WO2002076985A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
-
2000
- 2000-06-21 EA EA200200078A patent/EA005287B1/ru not_active IP Right Cessation
- 2000-06-21 SK SK354-2002A patent/SK3542002A3/sk not_active Application Discontinuation
- 2000-06-21 IL IL14861400A patent/IL148614A0/xx unknown
- 2000-06-21 YU YU18502A patent/YU18502A/sh unknown
- 2000-06-21 EE EEP200200140A patent/EE200200140A/xx unknown
- 2000-06-21 DZ DZ003186A patent/DZ3186A1/xx active
- 2000-06-21 KR KR1020027003387A patent/KR20020027649A/ko not_active Application Discontinuation
- 2000-06-21 US US10/070,530 patent/US7169778B2/en not_active Expired - Fee Related
- 2000-06-21 EP EP00941604A patent/EP1409487A1/en not_active Withdrawn
- 2000-06-21 NZ NZ516872A patent/NZ516872A/en unknown
- 2000-06-21 PL PL00353269A patent/PL353269A1/xx not_active Application Discontinuation
- 2000-06-21 CN CN00812620A patent/CN1373763A/zh active Pending
- 2000-06-21 AP APAP/P/2002/002479A patent/AP2002002479A0/en unknown
- 2000-06-21 JP JP2001523402A patent/JP2003509425A/ja not_active Abandoned
- 2000-06-21 AU AU56295/00A patent/AU777468B2/en not_active Ceased
- 2000-06-21 WO PCT/US2000/017037 patent/WO2001019825A1/en not_active Application Discontinuation
- 2000-06-21 CZ CZ2002846A patent/CZ2002846A3/cs unknown
- 2000-06-21 HU HU0202713A patent/HUP0202713A3/hu unknown
- 2000-06-21 CA CA002393896A patent/CA2393896A1/en not_active Abandoned
- 2000-06-21 MX MXPA02001108A patent/MXPA02001108A/es active IP Right Grant
- 2000-06-21 BR BR0013952-1A patent/BR0013952A/pt not_active Application Discontinuation
- 2000-06-21 OA OA1200200058A patent/OA12010A/en unknown
-
2002
- 2002-01-31 ZA ZA200200896A patent/ZA200200896B/en unknown
- 2002-02-11 CR CR6586A patent/CR6586A/es not_active Application Discontinuation
- 2002-03-12 MA MA26550A patent/MA26819A1/fr unknown
- 2002-03-13 IS IS6298A patent/IS6298A/is unknown
- 2002-03-13 NO NO20021239A patent/NO20021239L/no not_active Application Discontinuation
- 2002-04-10 BG BG106594A patent/BG106594A/xx unknown
-
2003
- 2003-02-18 HK HK03101140.4A patent/HK1048992A1/zh unknown
-
2006
- 2006-10-27 US US11/553,935 patent/US20070049600A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA200200078A1 (ru) | 2002-12-26 |
EP1409487A1 (en) | 2004-04-21 |
CA2393896A1 (en) | 2001-03-22 |
YU18502A (sh) | 2004-12-31 |
IL148614A0 (en) | 2002-09-12 |
BR0013952A (pt) | 2002-05-14 |
JP2003509425A (ja) | 2003-03-11 |
MXPA02001108A (es) | 2002-08-20 |
DZ3186A1 (fr) | 2001-03-22 |
US20030130286A1 (en) | 2003-07-10 |
WO2001019825A1 (en) | 2001-03-22 |
US20070049600A1 (en) | 2007-03-01 |
NO20021239D0 (no) | 2002-03-13 |
HUP0202713A2 (hu) | 2002-12-28 |
BG106594A (en) | 2002-12-29 |
MA26819A1 (fr) | 2004-12-20 |
EA005287B1 (ru) | 2004-12-30 |
CN1373763A (zh) | 2002-10-09 |
NO20021239L (no) | 2002-03-13 |
AP2002002479A0 (en) | 2002-06-30 |
AU5629500A (en) | 2001-04-17 |
HUP0202713A3 (en) | 2005-02-28 |
US7169778B2 (en) | 2007-01-30 |
OA12010A (en) | 2006-04-19 |
SK3542002A3 (en) | 2003-04-01 |
PL353269A1 (en) | 2003-11-03 |
CZ2002846A3 (cs) | 2003-02-12 |
AU777468B2 (en) | 2004-10-21 |
IS6298A (is) | 2002-03-13 |
EE200200140A (et) | 2003-04-15 |
HK1048992A1 (zh) | 2003-04-25 |
KR20020027649A (ko) | 2002-04-13 |
NZ516872A (en) | 2003-10-31 |
CR6586A (es) | 2004-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200200896B (en) | Pteridinones as kinase inhibitors. | |
JP2002516327A5 (es) | ||
CN102015700B (zh) | 抗菌稠合噻唑 | |
Lin et al. | Synthesis and evaluation of 2, 7-diamino-thiazolo [4, 5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors | |
Abdellatif et al. | Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment | |
KR101472607B1 (ko) | 지질 키나제 및 mTOR의 이중 억제제로서의 이미다조퀴놀린 | |
US20050026938A1 (en) | Purine inhibitors of protein kinases, G proteins and polymerases | |
KR20190099209A (ko) | 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물 | |
Gangjee et al. | 2, 4-Diamino-5-methyl-6-substituted arylthio-furo [2, 3-d] pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors | |
JP2004516297A (ja) | サイクリン依存性キナーゼ(cdk)及びグリコーゲンシンターゼキナーゼ−3(gsk−3)の阻害剤 | |
BRPI0913031A2 (pt) | derivados de quinolina e quinoxalinas como inibidores de proteína tirosina quinase, seus usos e processo de fabricação, bem como composições farmacêuticas e combinação que os compreende | |
KR20020065939A (ko) | 피리도[2,3-d]피리미딘-2,7-디아민 카이나제 억제제 | |
EP1841769A2 (fr) | Derives de la purine, compositions les contenant et leurs utilisation contre le cancer | |
EP2582675B1 (en) | Compounds for treating proliferative disorders | |
Kumar et al. | Medicinal chemistry perspective of pyrido [2, 3-d] pyrimidines as anticancer agents | |
Renau et al. | Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4-and 4, 6-substituents on the antiviral activity of pyrrolo [2, 3-d] pyrimidines | |
Shi et al. | Discovery of a novel series of imidazo [1′, 2’: 1, 6] pyrido [2, 3-d] pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors | |
Hennequin et al. | Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent | |
Choi et al. | Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino) ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl) pyrazolo [1, 5-α] pyrimidin-7-amine | |
Elumalai et al. | Antimicrobial and in vitro cytotoxicity of novel sulphanilamide condensed 1, 2, 3, 4-tetrahydropyrimidines | |
Zhai et al. | Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors | |
Tian et al. | Synthesis and biological evaluation of 2, 6-disubstituted-9H-purine, 2, 4-disubstitued-thieno [3, 2-d] pyrimidine and-7H-pyrrolo [2, 3-d] pyrimidine analogues as novel CHK1 inhibitors | |
Jeong et al. | Selective and potent small-molecule inhibitors of PI3Ks | |
Ye et al. | Design, synthesis and molecular docking analysis of some novel 7-[(quinolin-6-yl) methyl] purines as potential c-Met inhibitors | |
AU2022315201A1 (en) | Inhibitors targeting ubiquitin specific protease 7 (usp7) |